

# Jennifer G Robinson

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/4517658/jennifer-g-robinson-publications-by-citations.pdf>

**Version:** 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

286  
papers

25,626  
citations

64  
h-index

157  
g-index

321  
ext. papers

30,163  
ext. citations

7.4  
avg, IF

6.76  
L-index

#	Paper	IF	Citations
286	2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 66, 1770-185	15.1	2794
285	2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i> , <b>2014</b> , 129, S1-45	16.7	2786
284	2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i> , <b>2014</b> , 129, S49-103	16.7	2093
283	2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 63, 2935-2959	15.1	1625
282	Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. <i>New England Journal of Medicine</i> , <b>2015</b> , 372, 1489-99	59.2	1347
281	Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. <i>New England Journal of Medicine</i> , <b>2015</b> , 372, 1500-9	59.2	1081
280	Loss-of-function mutations in APOC3, triglycerides, and coronary disease. <i>New England Journal of Medicine</i> , <b>2014</b> , 371, 22-31	59.2	721
279	Dietary Fats and Cardiovascular Disease: A Presidential Advisory From the American Heart Association. <i>Circulation</i> , <b>2017</b> , 136, e1-e23	16.7	587
278	Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes. <i>New England Journal of Medicine</i> , <b>2016</b> , 375, 2144-2153	59.2	418
277	HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. <i>Lancet, The</i> , <b>2015</b> , 385, 351-61	40	409
276	Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2014</b> , 311, 1870-82	27.4	347
275	Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis. <i>Journal of the American College of Cardiology</i> , <b>2005</b> , 46, 1855-62	15.1	331
274	Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. <i>Journal of Clinical Lipidology</i> , <b>2011</b> , 5, S1-8	4.9	329
273	Noninvasive pulse wave analysis for the early detection of vascular disease. <i>Hypertension</i> , <b>1995</b> , 26, 503-8.5		314
272	Optimism, cynical hostility, and incident coronary heart disease and mortality in the Women's Health Initiative. <i>Circulation</i> , <b>2009</b> , 120, 656-62	16.7	307
271	Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk. <i>Journal of the American College of Cardiology</i> , <b>2009</b> , 53, 316-22	15.1	280
270	Cognitive Function in a Randomized Trial of Evolocumab. <i>New England Journal of Medicine</i> , <b>2017</b> , 377, 633-643	59.2	263

269	Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study. <i>American Heart Journal</i> , <b>2015</b> , 169, 906-915.e13	4.9	251
268	Association of low-frequency and rare coding-sequence variants with blood lipids and coronary heart disease in 56,000 whites and blacks. <i>American Journal of Human Genetics</i> , <b>2014</b> , 94, 223-32	11	233
267	Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering: A Systematic Review and Meta-analysis. <i>JAMA - Journal of the American Medical Association</i> , <b>2018</b> , 319, 1566-1579	27.4	205
266	Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized Phase 3 trial. <i>International Journal of Cardiology</i> , <b>2014</b> , 176, 55-61	3.2	204
265	Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes). <i>Journal of the American College of Cardiology</i> , <b>2013</b> , 62, 1575-9	15.1	199
264	Validity of diabetes self-reports in the Women's Health Initiative: comparison with medication inventories and fasting glucose measurements. <i>Clinical Trials</i> , <b>2008</b> , 5, 240-7	2.2	194
263	Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. <i>Journal of Clinical Lipidology</i> , <b>2011</b> , 5, 133-140	4.9	181
262	Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2015</b> , 100, 3140-8	5.6	176
261	Whole-exome sequencing identifies rare and low-frequency coding variants associated with LDL cholesterol. <i>American Journal of Human Genetics</i> , <b>2014</b> , 94, 233-45	11	170
260	Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association. <i>Circulation</i> , <b>2019</b> , 140, e673-e691	16.7	169
259	Comparison of the Framingham and Reynolds Risk scores for global cardiovascular risk prediction in the multiethnic Women's Health Initiative. <i>Circulation</i> , <b>2012</b> , 125, 1748-56, S1-11	16.7	168
258	Antiatherosclerotic and antithrombotic effects of omega-3 fatty acids. <i>American Journal of Cardiology</i> , <b>2006</b> , 98, 39i-49i	3	140
257	Treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: synopsis of the 2013 American College of Cardiology/American Heart Association cholesterol guideline. <i>Annals of Internal Medicine</i> , <b>2014</b> , 160, 339-43	8	136
256	Safety of Very Low Low-Density Lipoprotein Cholesterol Levels With Alirocumab: Pooled Data From Randomized Trials. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 69, 471-482	15.1	133
255	Isoflavone-rich or isoflavone-poor soy protein does not reduce menopausal symptoms during 24 weeks of treatment. <i>Menopause</i> , <b>2001</b> , 8, 17-26	2.5	131
254	Long-term effects on cognitive function of postmenopausal hormone therapy prescribed to women aged 50 to 55 years. <i>JAMA Internal Medicine</i> , <b>2013</b> , 173, 1429-36	11.5	124
253	Safety of aggressive lipid management. <i>Journal of the American College of Cardiology</i> , <b>2007</b> , 49, 1753-62	15.1	123
252	Electronic health records based phenotyping in next-generation clinical trials: a perspective from the NIH Health Care Systems Collaboratory. <i>Journal of the American Medical Informatics Association: JAMIA</i> , <b>2013</b> , 20, e226-31	8.6	121

251	Maternal hyperlipidemia and the risk of preeclampsia: a meta-analysis. <i>American Journal of Epidemiology</i> , <b>2014</b> , 180, 346-58	3.8	117
250	Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data. <i>Lancet Diabetes and Endocrinology</i> , <b>2016</b> , 4, 403-10	18.1	110
249	No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies. <i>European Heart Journal</i> , <b>2016</b> , 37, 2981-2989	9.5	108
248	Sleep duration, cognitive decline, and dementia risk in older women. <i>Alzheimeris and Dementia</i> , <b>2016</b> , 12, 21-33	1.2	99
247	Effect of Alirocumab on Lipoprotein(a) Over 1.5 Years (from the Phase 3 ODYSSEY Program). <i>American Journal of Cardiology</i> , <b>2017</b> , 119, 40-46	3	98
246	Genome-wide characterization of shared and distinct genetic components that influence blood lipid levels in ethnically diverse human populations. <i>American Journal of Human Genetics</i> , <b>2013</b> , 92, 904-16	11.1	97
245	Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial. <i>European Heart Journal</i> , <b>2010</b> , 31, 480-8	9.5	96
244	Determining When to Add Nonstatin Therapy: A Quantitative Approach. <i>Journal of the American College of Cardiology</i> , <b>2016</b> , 68, 2412-2421	15.1	95
243	Trans-ethnic fine-mapping of lipid loci identifies population-specific signals and allelic heterogeneity that increases the trait variance explained. <i>PLoS Genetics</i> , <b>2013</b> , 9, e1003379	6	94
242	Multimarker prediction of coronary heart disease risk: the Women's Health Initiative. <i>Journal of the American College of Cardiology</i> , <b>2010</b> , 55, 2080-91	15.1	92
241	Effect of long-chain n-3 fatty acids and lutein + zeaxanthin supplements on cardiovascular outcomes: results of the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. <i>JAMA Internal Medicine</i> , <b>2014</b> , 174, 763-71	11.5	90
240	Genome-wide association and population genetic analysis of C-reactive protein in African American and Hispanic American women. <i>American Journal of Human Genetics</i> , <b>2012</b> , 91, 502-12	11	90
239	Treatment of adults with familial hypercholesterolemia and evidence for treatment: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. <i>Journal of Clinical Lipidology</i> , <b>2011</b> , 5, S18-29	4.9	90
238	Fatty acid biomarkers of dairy fat consumption and incidence of type 2 diabetes: A pooled analysis of prospective cohort studies. <i>PLoS Medicine</i> , <b>2018</b> , 15, e1002670	11.6	89
237	Influence of type 2 diabetes on brain volumes and changes in brain volumes: results from the Women's Health Initiative Magnetic Resonance Imaging studies. <i>Diabetes Care</i> , <b>2013</b> , 36, 90-7	14.6	88
236	Meta-analysis of comparison of effectiveness of lowering apolipoprotein B versus low-density lipoprotein cholesterol and nonhigh-density lipoprotein cholesterol for cardiovascular risk reduction in randomized trials. <i>American Journal of Cardiology</i> , <b>2012</b> , 110, 1468-76	3	86
235	Resilience to chronic stress is mediated by noradrenergic regulation of dopamine neurons. <i>Nature Neuroscience</i> , <b>2016</b> , 19, 560-3	25.5	84
234	Effect of 5 y of calcium plus vitamin D supplementation on change in circulating lipids: results from the Women's Health Initiative. <i>American Journal of Clinical Nutrition</i> , <b>2010</b> , 91, 894-9	7	84

233	Cardiovascular disease and cognitive decline in postmenopausal women: results from the Women's Health Initiative Memory Study. <i>Journal of the American Heart Association</i> , <b>2013</b> , 2, e000369	6	80
232	Racial/Ethnic and gender gaps in the use of and adherence to evidence-based preventive therapies among elderly Medicare Part D beneficiaries after acute myocardial infarction. <i>Circulation</i> , <b>2014</b> , 129, 754-63	16.7	79
231	Management of familial hypercholesterolemia: a review of the recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. <i>Journal of Managed Care Pharmacy</i> , <b>2013</b> , 19, 139-49		79
230	Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia not adequately controlled with current lipid-lowering therapy: design and rationale of the ODYSSEY FH studies. <i>Cardiovascular Drugs and Therapy</i> , <b>2014</b> , 28, 281-9	3.9	78
229	Optogenetic Activation of Septal Glutamatergic Neurons Drive Hippocampal Theta Rhythms. <i>Journal of Neuroscience</i> , <b>2016</b> , 36, 3016-23	6.6	76
228	Fatty acid consumption and risk of fracture in the Women's Health Initiative. <i>American Journal of Clinical Nutrition</i> , <b>2010</b> , 92, 1452-60	7	73
227	Safety of Alirocumab (A PCSK9 Monoclonal Antibody) from 14 Randomized Trials. <i>American Journal of Cardiology</i> , <b>2016</b> , 118, 1805-1811	3	70
226	Patient-Reported Reasons for Declining or Discontinuing Statin Therapy: Insights From the PALM Registry. <i>Journal of the American Heart Association</i> , <b>2019</b> , 8, e011765	6	69
225	Lack of association between 25(OH)D levels and incident type 2 diabetes in older women. <i>Diabetes Care</i> , <b>2011</b> , 34, 628-34	14.6	69
224	Quantifying rare, deleterious variation in 12 human cytochrome P450 drug-metabolism genes in a large-scale exome dataset. <i>Human Molecular Genetics</i> , <b>2014</b> , 23, 1957-63	5.6	68
223	Use of Medicare data to identify coronary heart disease outcomes in the Women's Health Initiative. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2014</b> , 7, 157-62	5.8	67
222	Curing atherosclerosis should be the next major cardiovascular prevention goal. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 63, 2779-85	15.1	62
221	Sex Differences in the Use of Statins in Community Practice. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2019</b> , 12, e005562	5.8	61
220	Soy protein intake by perimenopausal women does not affect circulating lipids and lipoproteins or coagulation and fibrinolytic factors. <i>Journal of Nutrition</i> , <b>2001</b> , 131, 2280-7	4.1	61
219	Multi-ancestry genome-wide gene-smoking interaction study of 387,272 individuals identifies new loci associated with serum lipids. <i>Nature Genetics</i> , <b>2019</b> , 51, 636-648	36.3	59
218	A Large-Scale Multi-ancestry Genome-wide Study Accounting for Smoking Behavior Identifies Multiple Significant Loci for Blood Pressure. <i>American Journal of Human Genetics</i> , <b>2018</b> , 102, 375-400	11	59
217	Efficacy and Safety of Alirocumab 150mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study. <i>Journal of the American Heart Association</i> , <b>2016</b> , 5,	6	59
216	Evaluation of the metabochip genotyping array in African Americans and implications for fine mapping of GWAS-identified loci: the PAGE study. <i>PLoS ONE</i> , <b>2012</b> , 7, e35651	3.7	59

215	Vitamin D intake and season modify the effects of the GC and CYP2R1 genes on 25-hydroxyvitamin D concentrations. <i>Journal of Nutrition</i> , <b>2013</b> , 143, 17-26	4.1	56
214	Fish intake and the risk of incident heart failure: the Women's Health Initiative. <i>Circulation: Heart Failure</i> , <b>2011</b> , 4, 404-13	7.6	56
213	Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study). <i>American Journal of Cardiology</i> , <b>2009</b> , 103, 1694-702	3	55
212	Conjugated equine estrogens and peripheral arterial disease risk: the Women's Health Initiative. <i>American Heart Journal</i> , <b>2006</b> , 152, 170-6	4.9	53
211	The impact of birth weight on cardiovascular disease risk in the Women's Health Initiative. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , <b>2016</b> , 26, 239-45	4.5	52
210	Correcting the effects of -20 °C storage and aliquot size on erythrocyte fatty acid content in the Women's Health Initiative. <i>Lipids</i> , <b>2012</b> , 47, 835-46	1.6	51
209	Nonstatin Low-Density Lipoprotein-Lowering Therapy and Cardiovascular Risk Reduction-Statement From ATVB Council. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2015</b> , 35, 2269-80	9.4	48
208	Association of Patient Perceptions of Cardiovascular Risk and Beliefs on Statin Drugs With Racial Differences in Statin Use: Insights From the Patient and Provider Assessment of Lipid Management Registry. <i>JAMA Cardiology</i> , <b>2018</b> , 3, 739-748	16.2	48
207	Adherence Tradeoff to Multiple Preventive Therapies and All-Cause Mortality After Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 70, 1543-1554	15.1	48
206	Is it time for a cardiovascular primary prevention trial in the elderly?. <i>Stroke</i> , <b>2007</b> , 38, 441-50	6.7	48
205	Low-fat dietary pattern and cardiovascular disease: results from the Women's Health Initiative randomized controlled trial. <i>American Journal of Clinical Nutrition</i> , <b>2017</b> , 106, 35-43	7	47
204	Prospective association of vitamin D concentrations with mortality in postmenopausal women: results from the Women's Health Initiative (WHI). <i>American Journal of Clinical Nutrition</i> , <b>2011</b> , 94, 1471-87		46
203	Lipoprotein particle concentrations may explain the absence of coronary protection in the women's health initiative hormone trials. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2008</b> , 28, 1666-71	9.4	46
202	Red blood cell polyunsaturated fatty acids and mortality in the Women's Health Initiative Memory Study. <i>Journal of Clinical Lipidology</i> , <b>2017</b> , 11, 250-259.e5	4.9	45
201	The 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk: a new paradigm supported by more evidence. <i>European Heart Journal</i> , <b>2015</b> , 36, 2110-2118	9.5	44
200	Eradicating the Burden of Atherosclerotic Cardiovascular Disease by Lowering Apolipoprotein B Lipoproteins Earlier in Life. <i>Journal of the American Heart Association</i> , <b>2018</b> , 7, e009778	6	43
199	A prospective study of the effect of hypertension and baseline blood pressure on cognitive decline and dementia in postmenopausal women: the Women's Health Initiative Memory Study. <i>Journal of the American Geriatrics Society</i> , <b>2008</b> , 56, 1449-58	5.6	42
198	Multi-ancestry study of blood lipid levels identifies four loci interacting with physical activity. <i>Nature Communications</i> , <b>2019</b> , 10, 376	17.4	41

197	Relationship of hypertension, blood pressure, and blood pressure control with white matter abnormalities in the Women's Health Initiative Memory Study (WHIMS)-MRI trial. <i>Journal of Clinical Hypertension</i> , <b>2010</b> , 12, 203-12	2.3	41
196	Cardiovascular risk in women with non-specific chest pain (from the Women's Health Initiative Hormone Trials). <i>American Journal of Cardiology</i> , <b>2008</b> , 102, 693-9	3	41
195	Multiancestry Genome-Wide Association Study of Lipid Levels Incorporating Gene-Alcohol Interactions. <i>American Journal of Epidemiology</i> , <b>2019</b> , 188, 1033-1054	3.8	39
194	Self-reported snoring and risk of cardiovascular disease among postmenopausal women (from the Women's Health Initiative). <i>American Journal of Cardiology</i> , <b>2013</b> , 111, 540-6	3	39
193	Birth weight and subsequent risk of cancer. <i>Cancer Epidemiology</i> , <b>2014</b> , 38, 538-43	2.8	38
192	Statins and diabetes risk: how real is it and what are the mechanisms?. <i>Current Opinion in Lipidology</i> , <b>2015</b> , 26, 228-35	4.4	38
191	A "poly-portfolio" for secondary prevention: a strategy to reduce subsequent events by up to 97% over five years. <i>American Journal of Cardiology</i> , <b>2005</b> , 95, 373-8	3	38
190	Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy. <i>Progress in Cardiovascular Diseases</i> , <b>2015</b> , 58, 19-31	8.5	37
189	Joint Associations of Diet, Lifestyle, and Genes with Age-Related Macular Degeneration. <i>Ophthalmology</i> , <b>2015</b> , 122, 2286-94	7.3	37
188	Low-fat dietary pattern and lipoprotein risk factors: the Women's Health Initiative Dietary Modification Trial. <i>American Journal of Clinical Nutrition</i> , <b>2010</b> , 91, 860-74	7	37
187	Lipid-lowering effects of statins: a comparative review. <i>Expert Opinion on Pharmacotherapy</i> , <b>2006</b> , 7, 1704-14		37
186	Combination therapy with ezetimibe and simvastatin to achieve aggressive LDL reduction. <i>Expert Review of Cardiovascular Therapy</i> , <b>2006</b> , 4, 461-76	2.5	37
185	Evaluation of the Pooled Cohort Risk Equations for Cardiovascular Risk Prediction in a Multiethnic Cohort From the Women's Health Initiative. <i>JAMA Internal Medicine</i> , <b>2018</b> , 178, 1231-1240	11.5	36
184	Efficacy and safety of alirocumab as add-on therapy in high-cardiovascular-risk patients with hypercholesterolemia not adequately controlled with atorvastatin (20 or 40 mg) or rosuvastatin (10 or 20 mg): design and rationale of the ODYSSEY OPTIONS Studies. <i>Clinical Cardiology</i> , <b>2014</b> , 37, 597-604	3.3	36
183	Effects of postmenopausal hormone therapy on incident atrial fibrillation: the Women's Health Initiative randomized controlled trials. <i>Circulation: Arrhythmia and Electrophysiology</i> , <b>2012</b> , 5, 1108-16	6.4	35
182	Enrollment in a brain magnetic resonance study: results from the Women's Health Initiative Memory Study Magnetic Resonance Imaging Study (WHIMS-MRI). <i>Academic Radiology</i> , <b>2007</b> , 14, 603-12	4.3	35
181	A novel telephone-based system for management of secondary prevention to a low-density lipoprotein cholesterol American Journal of Cardiology, <b>2000</b> , 85, 305-8	3	35
180	Omega-3 fatty acids and cognitive function in women. <i>Women's Health</i> , <b>2010</b> , 6, 119-34	3	34

179	Racial and ethnic differences in incident hospitalized heart failure in postmenopausal women: the Women's Health Initiative. <i>Circulation</i> , <b>2012</b> , 126, 688-96	16.7	34
178	Enhancing the value of PCSK9 monoclonal antibodies by identifying patients most likely to benefit. A consensus statement from the National Lipid Association. <i>Journal of Clinical Lipidology</i> , <b>2019</b> , 13, 525-537	4.9	33
177	Blood n-3 fatty acid levels and total and cause-specific mortality from 17 prospective studies. <i>Nature Communications</i> , <b>2021</b> , 12, 2329	17.4	33
176	Association between vitamin D status and age-related macular degeneration by genetic risk. <i>JAMA Ophthalmology</i> , <b>2015</b> , 133, 1171-9	3.9	32
175	Biomimetic strategies for engineering composite tissues. <i>Current Opinion in Biotechnology</i> , <b>2016</b> , 40, 64-74	11.4	32
174	Lipid management in contemporary community practice: Results from the Provider Assessment of Lipid Management (PALM) Registry. <i>American Heart Journal</i> , <b>2017</b> , 193, 84-92	4.9	32
173	Statin use and lipid levels in older adults: National Health and Nutrition Examination Survey, 2001 to 2006. <i>Journal of Clinical Lipidology</i> , <b>2010</b> , 4, 483-90	4.9	32
172	Management of the patient with statin intolerance. <i>Current Atherosclerosis Reports</i> , <b>2010</b> , 12, 48-57	6	32
171	Statins, angiotensin-converting enzyme inhibitors, and physical performance in older women. <i>Journal of the American Geriatrics Society</i> , <b>2012</b> , 60, 2206-14	5.6	31
170	EB fatty acids and domain-specific cognitive aging: secondary analyses of data from WHISCA. <i>Neurology</i> , <b>2013</b> , 81, 1484-91	6.5	31
169	Dalcetrapib: a review of Phase II data. <i>Expert Opinion on Investigational Drugs</i> , <b>2010</b> , 19, 795-805	5.9	31
168	The cross-sectional relationship between body mass index, waist-hip ratio, and cognitive performance in postmenopausal women enrolled in the Women's Health Initiative. <i>Journal of the American Geriatrics Society</i> , <b>2010</b> , 58, 1427-32	5.6	31
167	Cardiovascular Health and Incident Cardiovascular Disease and Cancer: The Women's Health Initiative. <i>American Journal of Preventive Medicine</i> , <b>2016</b> , 50, 236-40	6.1	31
166	Models for describing relations among the various statin drugs, low-density lipoprotein cholesterol lowering, pleiotropic effects, and cardiovascular risk. <i>American Journal of Cardiology</i> , <b>2008</b> , 101, 1009-15 <sup>3</sup>		29
165	Affecting behavior change in individuals with diabetes: findings from the Study to Help Improve Early Evaluation and Management of Risk Factors Leading to Diabetes (SHIELD). <i>The Diabetes Educator</i> , <b>2008</b> , 34, 1025-36	2.5	29
164	Can biomarkers identify women at increased stroke risk? The Women's Health Initiative Hormone Trials. <i>PLOS Clinical Trials</i> , <b>2007</b> , 2, e28		29
163	First trimester prenatal screening biomarkers and gestational diabetes mellitus: A systematic review and meta-analysis. <i>PLoS ONE</i> , <b>2018</b> , 13, e0201319	3.7	28
162	Challenges and Opportunities for the Prevention and Treatment of Cardiovascular Disease Among Young Adults: Report From a National Heart, Lung, and Blood Institute Working Group. <i>Journal of the American Heart Association</i> , <b>2020</b> , 9, e016115	6	28

161	PCSK9 Inhibitors and Cardiovascular Events. <i>New England Journal of Medicine</i> , <b>2015</b> , 373, 774	59.2	27
160	Association of fried food consumption with all cause, cardiovascular, and cancer mortality: prospective cohort study. <i>BMJ, The</i> , <b>2019</b> , 364, k5420	5.9	26
159	Diet drink consumption and the risk of cardiovascular events: a report from the Women's Health Initiative. <i>Journal of General Internal Medicine</i> , <b>2015</b> , 30, 462-8	4	26
158	Omega-3 fatty acid biomarkers and subsequent depressive symptoms. <i>International Journal of Geriatric Psychiatry</i> , <b>2014</b> , 29, 747-57	3.9	26
157	Evaluation of the American Heart Association cardiovascular disease prevention guideline for women. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2010</b> , 3, 128-34	5.8	25
156	Future issues, public policy, and public awareness of familial hypercholesterolemias: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. <i>Journal of Clinical Lipidology</i> , <b>2011</b> , 5, S46-51	4.9	24
155	Evidence-Based Policy Making: Assessment of the American Heart Association's Strategic Policy Portfolio: A Policy Statement From the American Heart Association. <i>Circulation</i> , <b>2016</b> , 133, e615-53	16.7	24
154	Atherosclerosis profile and incidence of cardiovascular events: a population-based survey. <i>BMC Cardiovascular Disorders</i> , <b>2009</b> , 9, 46	2.3	23
153	Efficacy and safety of ezetimibe and ezetimibe plus statin therapy in patients aged under 65, 65-74 and 75 years and older. <i>Aging Health</i> , <b>2007</b> , 3, 691-705		23
152	Red Blood Cell Fatty Acids and Incident Diabetes Mellitus in the Women's Health Initiative Memory Study. <i>PLoS ONE</i> , <b>2016</b> , 11, e0147894	3.7	23
151	Fine-mapping of lipid regions in global populations discovers ethnic-specific signals and refines previously identified lipid loci. <i>Human Molecular Genetics</i> , <b>2016</b> , 25, 5500-5512	5.6	22
150	Starting primary prevention earlier with statins. <i>American Journal of Cardiology</i> , <b>2014</b> , 114, 1437-42	3	22
149	Clinical utility of lipoprotein-associated phospholipase AII for cardiovascular disease prediction in a multiethnic cohort of women. <i>Clinical Chemistry</i> , <b>2012</b> , 58, 1352-63	5.5	22
148	Consistent LDL-C response with evolocumab among patient subgroups in PROFICIO: A pooled analysis of 3146 patients from phase 3 studies. <i>Clinical Cardiology</i> , <b>2018</b> , 41, 1328-1335	3.3	21
147	Alcohol consumption, hypertension, and total mortality among women. <i>American Journal of Hypertension</i> , <b>2009</b> , 22, 1212-8	2.3	21
146	Changes in Statin Adherence Following an Acute Myocardial Infarction Among Older Adults: Patient Predictors and the Association With Follow-Up With Primary Care Providers and/or Cardiologists. <i>Journal of the American Heart Association</i> , <b>2017</b> , 6,	6	20
145	Design and rationale for the Patient and Provider Assessment of Lipid Management (PALM) registry. <i>American Heart Journal</i> , <b>2015</b> , 170, 865-71	4.9	20
144	Erythrocyte omega-3 fatty acids are inversely associated with incident dementia: Secondary analyses of longitudinal data from the Women's Health Initiative Memory Study (WHIMS). <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , <b>2017</b> , 121, 68-75	2.8	20

143	Geographic variation in statin use for complex acute myocardial infarction patients: evidence of effective care?. <i>Medical Care</i> , <b>2014</b> , 52 Suppl 3, S37-44	3.1	20
142	Depressive Symptoms and Longitudinal Changes in Cognition: Women's Health Initiative Study of Cognitive Aging. <i>Journal of Geriatric Psychiatry and Neurology</i> , <b>2014</b> , 27, 94-102	3.8	19
141	Influence of Cardiovascular Risk Communication Tools and Presentation Formats on Patient Perceptions and Preferences. <i>JAMA Cardiology</i> , <b>2018</b> , 3, 1192-1199	16.2	19
140	ApoB in clinical care: Pro and Con. <i>Atherosclerosis</i> , <b>2019</b> , 282, 169-175	3.1	18
139	Maternal dyslipidemia and risk for preterm birth. <i>PLoS ONE</i> , <b>2018</b> , 13, e0209579	3.7	18
138	Efficacy and Safety of Alirocumab in Individuals with Diabetes Mellitus: Pooled Analyses from Five Placebo-Controlled Phase 3 Studies. <i>Diabetes Therapy</i> , <b>2018</b> , 9, 1317-1334	3.6	18
137	Fatty acids in the de novo lipogenesis pathway and incidence of type 2 diabetes: A pooled analysis of prospective cohort studies. <i>PLoS Medicine</i> , <b>2020</b> , 17, e1003102	11.6	17
136	Long-term treatment adherence to the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab in 6 ODYSSEY Phase III clinical studies with treatment duration of 1 to 2 years. <i>Journal of Clinical Lipidology</i> , <b>2017</b> , 11, 986-997	4.9	17
135	Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study). <i>Journal of Clinical Lipidology</i> , <b>2011</b> , 5, 474-82	4.9	17
134	Simvastatin: present and future perspectives. <i>Expert Opinion on Pharmacotherapy</i> , <b>2007</b> , 8, 2159-27	4	17
133	Elderly women diagnosed with nonspecific chest pain may be at increased cardiovascular risk. <i>Journal of Women's Health</i> , <b>2006</b> , 15, 1151-60	3	17
132	Comparison of lifestyle-based and traditional cardiovascular disease prediction in a multiethnic cohort of nonsmoking women. <i>Circulation</i> , <b>2014</b> , 130, 1466-73	16.7	16
131	What is the role of advanced lipoprotein analysis in practice?. <i>Journal of the American College of Cardiology</i> , <b>2012</b> , 60, 2607-15	15.1	16
130	Should We Use PPAR Agonists to Reduce Cardiovascular Risk?. <i>PPAR Research</i> , <b>2008</b> , 2008, 891425	4.3	16
129	The effects of transdermal testosterone and oestrogen therapy on dry eye in postmenopausal women: a randomised, placebo-controlled, pilot study. <i>British Journal of Ophthalmology</i> , <b>2017</b> , 101, 926-932	5.5	15
128	Insulin Resistance and Risk of Cardiovascular Disease in Postmenopausal Women: A Cohort Study From the Women's Health Initiative. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2015</b> , 8, 309-16	5.8	15
127	A multi-ancestry genome-wide study incorporating gene-smoking interactions identifies multiple new loci for pulse pressure and mean arterial pressure. <i>Human Molecular Genetics</i> , <b>2019</b> , 28, 2615-2633	5.6	14
126	Effects of Extended-Release Niacin Added to Simvastatin/Ezetimibe on Glucose and Insulin Values in AIM-HIGH. <i>American Journal of Medicine</i> , <b>2016</b> , 129, 753.e13-22	2.4	14

125	Counterpoint: Low-Density Lipoprotein Cholesterol Targets Are Not Needed in Lipid Treatment Guidelines. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2016</b> , 36, 586-90	9.4	14
124	Embedding clinical interventions into observational studies. <i>Contemporary Clinical Trials</i> , <b>2016</b> , 46, 100-105		14
123	The rationale, design, and baseline characteristics of the Women's Health Initiative Memory Study of Younger Women (WHIMS-Y). <i>Brain Research</i> , <b>2013</b> , 1514, 3-11	3.7	14
122	Prevalent but moderate variation across small geographic regions in patient nonadherence to evidence-based preventive therapies in older adults after acute myocardial infarction. <i>Medical Care</i> , <b>2014</b> , 52, 185-93	3.1	14
121	Development and validation of a clinical model for preconception and early pregnancy risk prediction of gestational diabetes mellitus in nulliparous women. <i>PLoS ONE</i> , <b>2019</b> , 14, e0215173	3.7	13
120	Prevalence and Management of Symptoms Associated With Statin Therapy in Community Practice: Insights From the PALM (Patient and Provider Assessment of Lipid Management) Registry. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2018</b> , 11, e004249	5.8	13
119	Age, abdominal obesity, and baseline high-sensitivity C-reactive protein are associated with low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B responses to ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome. <i>Journal of Clinical Lipidology</i> , <b>2013</b> , 7, 292-303	4.9	13
118	Lipid-lowering effects of ezetimibe and simvastatin in combination. <i>Expert Review of Cardiovascular Therapy</i> , <b>2011</b> , 9, 131-45	2.5	13
117	Subclinical hypothyroidism and risk for incident ischemic stroke among postmenopausal women. <i>Thyroid</i> , <b>2014</b> , 24, 1210-7	6.2	12
116	Genetic Predisposition to Dyslipidemia and Risk of Preeclampsia. <i>American Journal of Hypertension</i> , <b>2015</b> , 28, 915-23	2.3	12
115	Lipid-lowering therapy for the primary prevention of cardiovascular disease in the elderly: opportunities and challenges. <i>Drugs and Aging</i> , <b>2009</b> , 26, 917-31	4.7	12
114	Update on PPAR agonists: the clinical significance of FIELD and PROACTIVE. <i>Current Atherosclerosis Reports</i> , <b>2007</b> , 9, 64-71	6	12
113	n-3 Fatty Acid Biomarkers and Incident Type 2 Diabetes: An Individual Participant-Level Pooling Project of 20 Prospective Cohort Studies. <i>Diabetes Care</i> , <b>2021</b> , 44, 1133-1142	14.6	12
112	Association Between Preadmission Functional Status and Use and Effectiveness of Secondary Prevention Medications in Elderly Survivors of Acute Myocardial Infarction. <i>Journal of the American Geriatrics Society</i> , <b>2016</b> , 64, 526-35	5.6	12
111	It's Not Too Late to Improve Statin Adherence: Association Between Changes in Statin Adherence from Before to After Acute Myocardial Infarction and All-Cause Mortality. <i>Journal of the American Heart Association</i> , <b>2019</b> , 8, e011378	6	11
110	New strategies for the development of lipid-lowering therapies to reduce cardiovascular risk. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , <b>2018</b> , 4, 119-127	6.4	11
109	Guidelines for Management of Hyperlipidemia: Implications for Treatment of Patients with Stroke Secondary to Atherosclerotic Disease. <i>Current Neurology and Neuroscience Reports</i> , <b>2016</b> , 16, 24	6.6	11
108	The Relationship of Cardiovascular Disease to Physical Functioning in Women Surviving to Age 80 and Above in the Women's Health Initiative. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , <b>2016</b> , 71 Suppl 1, S42-53	6.4	11

107	Genetic Risk Score for Essential Hypertension and Risk of Preeclampsia. <i>American Journal of Hypertension</i> , <b>2016</b> , 29, 17-24	2.3	11
106	Metabolic syndrome cluster does not provide incremental prognostic information in patients with stable cardiovascular disease: A post hoc analysis of the AIM-HIGH trial. <i>Journal of Clinical Lipidology</i> , <b>2017</b> , 11, 1201-1211	4.9	10
105	Rationale and design of LAPLACE-2: a phase 3, randomized, double-blind, placebo- and ezetimibe-controlled trial evaluating the efficacy and safety of evolocumab in subjects with hypercholesterolemia on background statin therapy. <i>Clinical Cardiology</i> , <b>2014</b> , 37, 195-203	3.3	10
104	Another treatment gap: restarting secondary prevention medications: the Women's Health Initiative. <i>Journal of Clinical Lipidology</i> , <b>2010</b> , 4, 36-45	4.9	10
103	Practice-level variation in statin use and low-density lipoprotein cholesterol control in the United States: Results from the Patient and Provider Assessment of Lipid Management (PALM) registry. <i>American Heart Journal</i> , <b>2019</b> , 214, 113-124	4.9	9
102	Atherosclerosis stabilization with PCSK-9 inhibition: An evolving concept for cardiovascular prevention. <i>Atherosclerosis</i> , <b>2015</b> , 243, 593-7	3.1	9
101	Relationship between alirocumab, PCSK9, and LDL-C levels in four phase 3 ODYSSEY trials using 75 and 150mg doses. <i>Journal of Clinical Lipidology</i> , <b>2019</b> , 13, 979-988.e10	4.9	9
100	2013 ACC/AHA cholesterol guideline for reducing cardiovascular risk: what is so controversial?. <i>Current Atherosclerosis Reports</i> , <b>2014</b> , 16, 413	6	9
99	More Dynamic Than You Think: Hidden Aspects of Decision-Making. <i>Administrative Sciences</i> , <b>2017</b> , 7, 23	2.5	9
98	Trajectories of positive aging: observations from the women's health initiative study. <i>International Psychogeriatrics</i> , <b>2014</b> , 26, 1351-62	3.4	9
97	Clopidogrel and neuraxial block: the role of the PFA II and P2Y12 assays. <i>Regional Anesthesia and Pain Medicine</i> , <b>2010</b> , 35, 115	3.4	9
96	Attitudes about health and health-related behaviors in patients with cardiovascular disease or at elevated risk for cardiovascular disease. <i>Preventive Cardiology</i> , <b>2009</b> , 12, 136-43		9
95	Nonstatins and Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors: Role in Non-Familial Hypercholesterolemia. <i>Progress in Cardiovascular Diseases</i> , <b>2016</b> , 59, 165-171	8.5	9
94	Comparison of Cardiovascular Risk Factors for Coronary Heart Disease and Stroke Type in Women. <i>Journal of the American Heart Association</i> , <b>2018</b> , 7, e007514	6	9
93	Intensity of Lipid Lowering With Statin Therapy in Patients With Cerebrovascular Disease Versus Coronary Artery Disease: Insights from the PALM Registry. <i>Journal of the American Heart Association</i> , <b>2019</b> , 8, e013229	6	8
92	Statin use after acute myocardial infarction by patient complexity: are the rates right?. <i>Medical Care</i> , <b>2015</b> , 53, 324-31	3.1	8
91	Chart validation of inpatient ICD-9-CM administrative diagnosis codes for acute myocardial infarction (AMI) among intravenous immune globulin (IGIV) users in the Sentinel Distributed Database. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2018</b> , 27, 398-404	2.6	8
90	Emerging innovative therapeutic approaches targeting PCSK9 to lower lipids. <i>Clinical Pharmacology and Therapeutics</i> , <b>2016</b> , 99, 59-71	6.1	8

89	Correlates of Successful Aging in Racial and Ethnic Minority Women Age 80 Years and Older: Findings from the Women's Health Initiative. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , <b>2016</b> , 71 Suppl 1, S87-99	6.4	8
88	Association between different measures of blood pressure and coronary artery calcium in postmenopausal women. <i>Hypertension</i> , <b>2008</b> , 52, 833-40	8.5	8
87	Management of complex lipid abnormalities with a fixed dose combination of simvastatin and extended release niacin. <i>Vascular Health and Risk Management</i> , <b>2009</b> , 5, 31-43	4.4	8
86	Progenitor Cells of the Mandibular Condylar Cartilage. <i>Current Molecular Biology Reports</i> , <b>2015</b> , 1, 110-114	11.4	7
85	Exploring the interaction between SNP genotype and postmenopausal hormone therapy effects on stroke risk. <i>Genome Medicine</i> , <b>2012</b> , 4, 57	14.4	7
84	Big Data Cohort Extraction to Facilitate Machine Learning to Improve Statin Treatment. <i>Western Journal of Nursing Research</i> , <b>2017</b> , 39, 42-62	2	6
83	The extent to which statins have improved cardiovascular outcomes: Lessons from randomized trials and observational studies of "real world" practice in people with diabetes. <i>Diabetes, Obesity and Metabolism</i> , <b>2019</b> , 21 Suppl 1, 17-27	6.7	6
82	New insights into managing symptoms during statin therapy. <i>Progress in Cardiovascular Diseases</i> , <b>2019</b> , 62, 390-394	8.5	6
81	Lipid management beyond the guidelines. <i>Progress in Cardiovascular Diseases</i> , <b>2019</b> , 62, 384-389	8.5	6
80	The Relationship Between Serum 25-Hydroxyvitamin D Levels and Nuclear Cataract in the Carotenoid Age-Related Eye Study (CAREDS), an Ancillary Study of the Women's Health Initiative <b>2015</b> , 56, 4221-30		6
79	Investigational drugs targeting HDL-C metabolism and reverse cholesterol transport. <i>Future Lipidology</i> , <b>2007</b> , 2, 285-301		6
78	Association of Body Mass Index With Colorectal Cancer Risk by Genome-Wide Variants. <i>Journal of the National Cancer Institute</i> , <b>2021</b> , 113, 38-47	9.7	6
77	Identifying Patients for Nonstatin Therapy. <i>Reviews in Cardiovascular Medicine</i> , <b>2018</b> , 19, 1-8	3.9	6
76	Can We Cure Atherosclerosis?. <i>Reviews in Cardiovascular Medicine</i> , <b>2018</b> , 19, 20-24	3.9	6
75	Chronic Use of Aspirin and Total White Matter Lesion Volume: Results from the Women's Health Initiative Memory Study of Magnetic Resonance Imaging Study. <i>Journal of Stroke and Cerebrovascular Diseases</i> , <b>2017</b> , 26, 2128-2136	2.8	5
74	Early pregnancy prediction of gestational diabetes mellitus risk using prenatal screening biomarkers in nulliparous women. <i>Diabetes Research and Clinical Practice</i> , <b>2020</b> , 163, 108139	7.4	5
73	Temporal Trends of High-Intensity Statin Therapy Among Veterans Treated With Percutaneous Coronary Intervention. <i>Journal of the American Heart Association</i> , <b>2018</b> , 7,	6	5
72	Incidence of and Risk Factors for Severe Adverse Events in Elderly Patients Taking Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers after an Acute Myocardial Infarction. <i>Pharmacotherapy</i> , <b>2018</b> , 38, 29-41	5.8	5

71	Family history of myocardial infarction predicts incident coronary heart disease in postmenopausal women with diabetes: the Women's Health Initiative Observational Study. <i>Diabetes/Metabolism Research and Reviews</i> , <b>2009</b> , 25, 725-32	7.5	5
70	Cholesterol management: targeting a lower low-density lipoprotein cholesterol concentration increases adult treatment panel-III goal attainment. <i>American Journal of Cardiology</i> , <b>2006</b> , 97, 1667-9	3	5
69	Cardiovascular disease (CVD) risk scores, age, or years since menopause to predict cardiovascular disease in the Women's Health Initiative. <i>Menopause</i> , <b>2021</b> , 28, 610-618	2.5	5
68	Can atherosclerosis be cured?. <i>Current Opinion in Lipidology</i> , <b>2019</b> , 30, 477-484	4.4	5
67	Measurement of Low-Density Lipoprotein Cholesterol Levels in Primary and Secondary Prevention Patients: Insights From the PALM Registry. <i>Journal of the American Heart Association</i> , <b>2018</b> , 7, e009251	6	5
66	Reticular Pseudodrusen Characteristics and Associations in the Carotenoids in Age-Related Eye Disease Study 2 (CAREDS2), an Ancillary Study of the Women's Health Initiative. <i>Ophthalmology Retina</i> , <b>2021</b> , 5, 721-729	3.8	5
65	Identifying Patients for Nonstatin Therapy. <i>Reviews in Cardiovascular Medicine</i> , <b>2018</b> , 19, S1-S8	3.9	5
64	Serum lipid changes following the onset of depressive symptoms in postmenopausal women. <i>Psychiatry Research</i> , <b>2017</b> , 247, 282-287	9.9	4
63	Statin use and risk of haemorrhagic stroke in a community-based cohort of postmenopausal women: an observational study from the Women's Health Initiative. <i>BMJ Open</i> , <b>2015</b> , 5, e007075	3	4
62	Patterns of type 2 diabetes monitoring in rural towns: How does frequency of HbA1c and lipid testing compare with existing guidelines?. <i>Australian Journal of Rural Health</i> , <b>2016</b> , 24, 371-377	1.3	4
61	A uniform approach to modeling risk factor relationships for ischemic lesion prevalence and extent: the Women's Health Initiative Magnetic Resonance Imaging study. <i>Neuroepidemiology</i> , <b>2010</b> , 34, 55-62	5.4	4
60	Long-Term Trends in Hypertension and Elevated Blood Pressure Among U.S. Adults, 1999 to 2016. <i>Journal of the American College of Cardiology</i> , <b>2018</b> , 72, 2089-2091	15.1	4
59	A Comparison of Ezetimibe and Evolocumab for Atherogenic Lipid Reduction in Four Patient Populations: A Pooled Efficacy and Safety Analysis of Three Phase 3 Studies. <i>Cardiology and Therapy</i> , <b>2020</b> , 9, 447-465	2.8	3
58	Beliefs, risk perceptions, and lipid management among patients with and without diabetes: Results from the PALM registry. <i>American Heart Journal</i> , <b>2020</b> , 225, 88-96	4.9	3
57	Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers for Geriatric Ischemic Stroke Patients: Are the Rates Right?. <i>Journal of the American Heart Association</i> , <b>2018</b> , 7,	6	3
56	Genetic predisposition to elevated levels of C-reactive protein is associated with a decreased risk for preeclampsia. <i>Hypertension in Pregnancy</i> , <b>2017</b> , 36, 30-35	2	3
55	Benefits associated with achieving optimal risk factor levels for the primary prevention of cardiovascular disease in older men. <i>Journal of Clinical Lipidology</i> , <b>2012</b> , 6, 58-65	4.9	3
54	Is a statin as part of a polypill the answer?. <i>Current Atherosclerosis Reports</i> , <b>2009</b> , 11, 15-22	6	3

53	LDL reduction: how low should we go and is it safe?. <i>Current Cardiology Reports</i> , <b>2008</b> , 10, 481-7	4.2	3
52	Development of a comprehensive health-risk prediction tool for postmenopausal women. <i>Menopause</i> , <b>2019</b> , 26, 1385-1394	2.5	3
51	Potential for Net Benefit Should Guide Preventive Therapy. <i>Circulation</i> , <b>2017</b> , 135, 630-632	16.7	2
50	Statins and Primary Prevention of Cardiovascular Disease in Women: A Critical Appraisal of the Evidence. <i>American Journal of Lifestyle Medicine</i> , <b>2015</b> , 9, 114-129	1.9	2
49	Testing for type 2 diabetes in Indigenous Australians: guideline recommendations and current practice. <i>Medical Journal of Australia</i> , <b>2017</b> , 207, 206-210	4	2
48	Optimizing Statins and Ezetimibe in Guideline-Focused Management. <i>Cardiology Clinics</i> , <b>2018</b> , 36, 221-223	5	2
47	Haptoglobin Genotype as a Determinant of Benefit or Harm From Niacin for Participants With Diabetes. <i>Journal of the American College of Cardiology</i> , <b>2016</b> , 67, 2553-4	15.1	2
46	Roundtable discussion: Dietary fats in prevention of atherosclerotic cardiovascular disease. <i>Journal of Clinical Lipidology</i> , <b>2018</b> , 12, 574-582	4.9	2
45	Impact of cyclooxygenase inhibitors in the Women's Health Initiative hormone trials: secondary analysis of a randomized trial. <i>PLOS Clinical Trials</i> , <b>2006</b> , 1, e26		2
44	A Comparison of NCEP and Absolute Risk Stratification Methods for Lipid-Lowering Therapy in Middle-Aged Adults: The ARIC Study. The ARIC Investigators. <i>Preventive Cardiology</i> , <b>2001</b> , 4, 148-157		2
43	Effectiveness of a Novel Krill Oil Agent in Patients With Severe Hypertriglyceridemia: A Randomized Clinical Trial. <i>JAMA Network Open</i> , <b>2022</b> , 5, e2141898	10.4	2
42	Effects of menopausal hormone therapy on erythrocyte n-3 and n-6 PUFA concentrations in the Women's Health Initiative randomized trial. <i>American Journal of Clinical Nutrition</i> , <b>2021</b> , 113, 1700-1706	7	2
41	The future of lipid guidelines. <i>Current Opinion in Lipidology</i> , <b>2016</b> , 27, 585-591	4.4	2
40	Patient-Perceived Versus Actual Risk of Cardiovascular Disease and Associated Willingness to Consider and Use Prevention Therapy. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2021</b> , 14, e006548	5.8	2
39	Low Birth Weight and Risk of Later-Life Physical Disability in Women. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , <b>2017</b> , 72, 543-547	6.4	1
38	Treatment effect of alirocumab according to age group, smoking status, and hypertension: Pooled analysis from 10 randomized ODYSSEY studies. <i>Journal of Clinical Lipidology</i> , <b>2019</b> , 13, 735-743	4.9	1
37	Response to Letter Regarding Article, "Optimism, Cynical Hostility, and Incident Coronary Heart Disease and Mortality in the Women's Health Initiative". <i>Circulation</i> , <b>2010</b> , 121, e408	16.7	1
36	How low to target LDL?. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , <b>2006</b> , 2, 414-5		1

35	Comparison of effectiveness and safety of simvastatin in patients or =75 years of age with coronary, cerebral, or peripheral arterial disease. <i>American Journal of Cardiology</i> , <b>2002</b> , 90, 994-5	3	1
34	Clinical implications of the log linear association between LDL-C lowering and cardiovascular risk reduction: Greatest benefits when LDL-C >100 mg/dl. <i>PLoS ONE</i> , <b>2020</b> , 15, e0240166	3.7	1
33	A Population-Based Study of Simvastatin Drug-Drug Interactions in Cardiovascular Disease Patients. <i>AMIA Summits on Translational Science Proceedings</i> , <b>2020</b> , 2020, 664-673	1.1	1
32	Patient perceptions and use of non-statin lipid lowering therapy among patients with or at risk for atherosclerotic cardiovascular disease: Insights from the PALM registry. <i>Clinical Cardiology</i> , <b>2021</b> , 44, 863-870	3.3	1
31	Prognostic Utility of Risk Enhancers and Coronary Artery Calcium Score Recommended in the 2018 ACC/AHA Multisociety Cholesterol Treatment Guidelines Over the Pooled Cohort Equation: Insights From 3 Large Prospective Cohorts. <i>Journal of the American Heart Association</i> , <b>2021</b> , 10, e019589	6	1
30	The neuropsychology of statin intolerance. <i>Nature Reviews Cardiology</i> , <b>2021</b> , 18, 153-154	14.8	1
29	In search of self-awareness: results of the National Lipid Association 2010 Lipid Pulse membership survey. <i>Journal of Clinical Lipidology</i> , <b>2011</b> , 5, 12-7	4.9	0
28	Pharmacodynamic relationship between PCSK9, alirocumab, and LDL-C lowering in the ODYSSEY CHOICE I trial. <i>Journal of Clinical Lipidology</i> , <b>2020</b> , 14, 707-719	4.9	0
27	Risk Patterns and Mortality in Postmenopausal Women Using Latent Class Analysis. <i>American Journal of Preventive Medicine</i> , <b>2021</b> , 61, e225-e233	6.1	0
26	Changes in physical and mental health are associated with cardiovascular disease incidence in postmenopausal women. <i>Age and Ageing</i> , <b>2019</b> , 48, 448-453	3	0
25	Reply: Cost Effectiveness of Nonstatin-to-Statin Therapy. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 69, 1996	15.1	
24	Genetic Risk Scores for Maternal Lipid Levels and Their Association with Preterm Birth. <i>Lipids</i> , <b>2019</b> , 54, 641-650	1.6	
23	Overview of 2013 American College of Cardiology/American Heart Association cholesterol guideline for reducing cardiovascular risk. <i>Clinical Practice (London, England)</i> , <b>2014</b> , 11, 273-275	3	
22	Can We Vaccinate Against Atherosclerosis and Prevent Cardiovascular Disease?. <i>Current Cardiovascular Risk Reports</i> , <b>2013</b> , 7, 249-250	0.9	
21	Statins vs Early Hormone Therapy for the Primary Prevention of Cardiovascular Disease in Women. <i>Current Cardiovascular Risk Reports</i> , <b>2013</b> , 7, 163-165	0.9	
20	Coronary Heart Disease in Women & Men: Similar and Different. <i>Current Cardiovascular Risk Reports</i> , <b>2013</b> , 7, 423-424	0.9	
19	Statins for Primary Prevention in Adults Aged 75 Years or Older. <i>Annals of Internal Medicine</i> , <b>2015</b> , 163, 481	8	
18	Reply: Prevention and control of atherosclerosis: why are exercise and physical activity not getting the respect they deserve?. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 64, 1761	15.1	

- 17 Identification and Treatment of Women with Familial Hypercholesterolemia. *Current Cardiovascular Risk Reports*, **2012**, 6, 196-204 0.9
- 16 Lipids in Women **2013**, 965-974
- 15 Is there a future for CETP-inhibitor therapy?. *Clinical Investigation*, **2011**, 1, 367-370
- 14 How Low to Go for Primary Prevention?. *Current Cardiovascular Risk Reports*, **2010**, 4, 245-247 0.9
- 13 Managing cholesterol in the elderly. *Aging Health*, **2006**, 2, 623-638
- 12 Sharon Monteith, Advancing Sisterhood?: Interracial Friendships in Contemporary Southern Fiction (Athens: the University of Georgia Press, 2000, \$40). Pp. 241. ISBN 0 8203 2249 0.. *Journal of American Studies*, **2002**, 36, 513-570 0.1
- 11 Self-controlled assessment of thromboembolic event (TEE) risk following intravenous immune globulin (IGIV) in the U.S. (2006-2012). *Journal of Thrombosis and Thrombolysis*, **2021**, 1 5.1
- 10 Management of Elevated Low-Density Lipoprotein Cholesterol. *Fundamental and Clinical Cardiology*, **2006**, 255-294
- 9 Letter by Robinson Regarding Articles, "Bringing Back Targets to KMPROVEK Atherosclerotic Cardiovascular Disease Outcomes: The Duel for Dual Goals; Are Two Targets Better Than One?" and "Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT". *Circulation*, **2016**, 133, e461 16.7
- 8 The next treatment paradigm in cardiovascular prevention?. *Lancet, The*, **2019**, 394, 2129-2131 4.0
- 7 Primary Prevention of Atherosclerotic Cardiovascular Disease **2018**, 433-458
- 6 Meta-analysis of LDL-C Lowering and Mortality-Reply. *JAMA - Journal of the American Medical Association*, **2018**, 320, 1493-1494 27.4
- 5 Producing personalized statin treatment plans to optimize clinical outcomes using big data and machine learning.. *Journal of Biomedical Informatics*, **2022**, 104029 10.2
- 4 Clinical implications of the log linear association between LDL-C lowering and cardiovascular risk reduction: Greatest benefits when LDL-C >100 mg/dl **2020**, 15, e0240166
- 3 Clinical implications of the log linear association between LDL-C lowering and cardiovascular risk reduction: Greatest benefits when LDL-C >100 mg/dl **2020**, 15, e0240166
- 2 Clinical implications of the log linear association between LDL-C lowering and cardiovascular risk reduction: Greatest benefits when LDL-C >100 mg/dl **2020**, 15, e0240166
- 1 Clinical implications of the log linear association between LDL-C lowering and cardiovascular risk reduction: Greatest benefits when LDL-C >100 mg/dl **2020**, 15, e0240166